Manuel Monreal/X
Aug 31, 2025, 07:05
RIETE Registry Data: Manuel Monreal on VTE vs. Bleeding Risks in Cancer Patients
Manuel Monreal, coordinator of the RIETE registry, posted on X:
”The risk of the composite of fatal PE or recurrent VTE within 90 days is much higher than major bleeding in lung, breast, hematologic or pancreatic cancers
No major differences in GU or CI cancers
Should all cancer patients with acute VTE receive the same treatment strategy?”
Find it here.
Title: Variation in Venous Thromboembolism Outcomes Based on Primary Cancer Site: A RIETE Registry Analysis
Authors: Javier Trujillo-Santos, Cihan Ay, Behnood Bikdeli, David Jiménez, Aurora Villalobos, Luciano López-Jiménez, Montserrat Pérez-Pinar, Javier Pagán-Escribano, Maurizio Ciammaichella, Manuel Monreal
Stay updated with Hemostasis Today.
Aurora Villalobos
Behnood Bikdeli
Bleeding Risk
cancer
Cihan Ay
David Jimenez
Hematology
Hemostasis Today
Javier Pagán-Escribano
Javier Trujillo-Santos
Luciano López-Jiménez
Manuel Monreal
Maurizio Ciammaichella
Montserrat Pérez-Pinar
PE
Pulmonary embolism
RIETE registry
venous thromboembolism (VTE)
-
Jan 20, 2026, 16:34Fernanda Orsi Explores Brazilian Registry of Thrombotic Thrombocytopenic Purpura
-
Jan 20, 2026, 16:15Tareq Abadl on Bacterial Contamination of Platelets
-
Jan 20, 2026, 15:53Ruzanna Papyan on Neuroblastoma Risk Stratification in Real-World Settings
-
Jan 20, 2026, 13:35Omar Shaltout On Stories Behind Memorable Cases
-
Jan 20, 2026, 13:25Omotola Olasupo and Colleagues Present Comparative Safety of Hemophilia Therapies in Canada
-
Jan 20, 2026, 13:15Benjamin YQ Tan on Precision Lipid Management After Stroke
-
Jan 20, 2026, 13:08Antonio Paul on Blame Game in Transplantation: HLA vs Microbes
-
Jan 20, 2026, 12:33Dario Tuccinardi on Obesity as Cardiovascular Treatment Target
-
Jan 20, 2026, 12:18Ed Shovelin on CRP-A Utilization in Diverse Research Areas